c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus.

In previous work, we showed that telomeres of normal cells are organized within the 3D space of the interphase nucleus in a nonoverlapping and cell cycle-dependent manner. This order is distorted in tumor cell nuclei where telomeres are found in close association forming aggregates of various numbers and sizes. Here we show that c-Myc overexpression induces telomeric aggregations in the interphase nucleus. Directly proportional to the duration of c-Myc deregulation, we observe three or five cycles of telomeric aggregate formation in interphase nuclei. These cycles reflect the onset and propagation of breakage-bridge-fusion cycles that are initiated by end-to-end telomeric fusions of chromosomes. Subsequent to initial chromosomal breakages, new fusions follow and the breakage-bridge-fusion cycles continue. During this time, nonreciprocal translocations are generated. c-Myc-dependent remodeling of the organization of telomeres thus precedes the onset of genomic instability and subsequently leads to chromosomal rearrangements. Our findings reveal that c-Myc possesses the ability to structurally modify chromosomes through telomeric fusions, thereby reorganizing the genetic information.

[1]  S. Thorgeirsson,et al.  Dysregulation of DNA Repair Pathways in a Transforming Growth Factor α/c-myc Transgenic Mouse Model of Accelerated Hepatocarcinogenesis , 2003, Laboratory Investigation.

[2]  Kou-Juey Wu,et al.  c-Myc Directly Regulates the Transcription of the NBS1 Gene Involved in DNA Double-strand Break Repair * , 2003, Journal of Biological Chemistry.

[3]  B. Mcclintock,et al.  The Stability of Broken Ends of Chromosomes in Zea Mays. , 1941, Genetics.

[4]  K. Pienta,et al.  Cancer as a disease of DNA organization and dynamic cell structure. , 1989, Cancer research.

[5]  J A Bond,et al.  Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. , 1998, The American journal of pathology.

[6]  S. Mai,et al.  Overexpression of c-myc precedes amplification of the gene encoding dihydrofolate reductase. , 1994, Gene.

[7]  S. Grénman,et al.  In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen. , 1988, Gynecologic oncology.

[8]  Thomas Cremer,et al.  Chromosome order in HeLa cells changes during mitosis and early G1, but is stably maintained during subsequent interphase stages , 2003, The Journal of cell biology.

[9]  E. B. Wilson.  Probable Inference, the Law of Succession, and Statistical Inference , 1927 .

[10]  J. Londoño-Vallejo.  Telomere length heterogeneity and chromosome instability. , 2004, Cancer letters.

[11]  S. Mai,et al.  Genomic instability and apoptosis are frequent in p53 deficient young mice , 1997, Oncogene.

[12]  A. Parreira,et al.  The nuclear topography of ABL, BCR, PML, and RARalpha genes: evidence for gene proximity in specific phases of the cell cycle and stages of hematopoietic differentiation. , 1999, Blood.

[13]  Tatjana Marinkovic,et al.  Reversible lymphomagenesis in conditionally c‐MYC expressing mice , 2004, International journal of cancer.

[14]  Daniele Zink,et al.  Nuclear structure in cancer cells , 2004, Nature Reviews Cancer.

[15]  D. S. Coffey,et al.  Nuclear matrix localization of high mobility group protein I(Y) in a transgenic mouse model for prostate cancer , 2003, Journal of cellular biochemistry.

[16]  Bas van Steensel,et al.  TRF2 Protects Human Telomeres from End-to-End Fusions , 1998, Cell.

[17]  T. Littlewood,et al.  Chromosomal and extrachromosomal instability of the cyclin D2 gene is induced by Myc overexpression. , 1999, Neoplasia.

[18]  Kenneth Chu,et al.  Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.

[19]  Tom Misteli,et al.  Chromosome positioning in the interphase nucleus. , 2002, Trends in cell biology.

[20]  C. Allis,et al.  Increased Ser-10 Phosphorylation of Histone H3 in Mitogen-stimulated and Oncogene-transformed Mouse Fibroblasts* , 1999, The Journal of Biological Chemistry.

[21]  Lynda Chin,et al.  Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice , 2000, Nature.

[22]  S. Mai,et al.  c-Myc overexpression associated DHFR gene amplification in hamster, rat, mouse and human cell lines. , 1996, Oncogene.

[23]  S. Mai,et al.  FISH : a practical approach , 2002 .

[24]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[25]  Tom Misteli,et al.  Tissue-specific spatial organization of genomes , 2004, Genome Biology.

[26]  L. Schaefer,et al.  Generalized approach for accelerated maximum likelihood based image restoration applied to three‐dimensional fluorescence microscopy , 2001, Journal of microscopy.

[27]  D. Felsher,et al.  Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Thierry Fest,et al.  c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis , 2002, Oncogene.

[29]  D. Gisselsson,et al.  Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Hande,et al.  Telomere Length Dynamics and Chromosomal Instability in Cells Derived from Telomerase Null Mice , 1999, The Journal of cell biology.

[31]  G R Stark,et al.  Fusions near telomeres occur very early in the amplification of CAD genes in Syrian hamster cells. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  G. Evan,et al.  A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. , 1995, Nucleic acids research.

[33]  S. Mai,et al.  c-Myc-induced extrachromosomal elements carry active chromatin. , 2003, Neoplasia.

[34]  E. Prochownik,et al.  MYC oncogenes and human neoplastic disease , 1999, Oncogene.

[35]  S. Grénman,et al.  In vitro growth regulation of endometrial carcinoma cells by tamoxifen and medroxyprogesterone acetate. , 1988, Gynecologic oncology.

[36]  J. Davie,et al.  Ras‐associated nuclear structural change appears functionally significant and independent of the mitotic signaling pathway , 1998, Journal of cellular biochemistry.

[37]  J. Murnane,et al.  Chromosome rearrangements resulting from telomere dysfunction and their role in cancer , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[38]  Thomas Cremer,et al.  Cell nucleus: Chromosome dynamics in nuclei of living cells , 1998, Current Biology.

[39]  D. Ward,et al.  Cell cycle-dependent distribution of telomeres, centromeres, and chromosome-specific subsatellite domains in the interphase nucleus of mouse lymphocytes. , 1993, Experimental cell research.

[40]  D. Felsher,et al.  Transient excess of MYC activity can elicit genomic instability and tumorigenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Tom Misteli,et al.  Conservation of Relative Chromosome Positioning in Normal and Cancer Cells , 2002, Current Biology.

[42]  S. Mai,et al.  c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene , 2002, Oncogene.

[43]  S. Mai,et al.  Deregulated expression of c-Myc in a translocation-negative plasmacytoma on extrachromosomal elements that carry IgH and myc genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Tom Misteli,et al.  Spatial proximity of translocation-prone gene loci in human lymphomas , 2003, Nature Genetics.

[45]  R. DePinho,et al.  Cancer chromosomes in crisis , 2004, Nature Genetics.

[46]  R K Ward,et al.  Telomere length measurements using digital fluorescence microscopy. , 1999, Cytometry.

[47]  G. Klein,et al.  Rearrangements of the telomeric region of mouse chromosome 11 in Pre-B ABL/MYC cells revealed by mBANDing, spectral karyotyping, and fluorescence in-situ hybridization with a subtelomeric probe , 2005, Chromosome Research.

[48]  G. Wahl,et al.  c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. , 2002, Molecular cell.

[49]  Roland Eils,et al.  Visualizing telomere dynamics in living mammalian cells using PNA probes , 2003, The EMBO journal.

[50]  W. Bickmore,et al.  Re-modelling of nuclear architecture in quiescent and senescent human fibroblasts , 2000, Current Biology.

[51]  Andrea Cocito,et al.  Genomic targets of the human c-Myc protein. , 2003, Genes & development.

[52]  M. Potter,et al.  The c-myc story: where we've been, where we seem to be going. , 1997, Current topics in microbiology and immunology.

[53]  W. Isaacs,et al.  High mobility group protein I(Y): a candidate architectural protein for chromosomal rearrangements in prostate cancer cells. , 2002, Cancer research.

[54]  Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein , 2005, Oncogene.

[55]  G. Evan,et al.  Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression , 2002, Cell.

[56]  S. Artandi.  Telomere shortening and cell fates in mouse models of neoplasia. , 2002, Trends in molecular medicine.

[57]  Christopher H. Contag,et al.  MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer , 2004, Nature.

[58]  K. Nielsen,et al.  Telomere erosion varies during in vitro aging of normal human fibroblasts from young and adult donors. , 2000, Cancer research.

[59]  M. Potter,et al.  Nonrandom chromosomal change (trisomy 11) in murine plasmacytomas induced by an ABL-MYC retrovirus. , 1995, Cancer research.

[60]  S. Mai,et al.  c-Myc-induced genomic instability. , 2003, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[61]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[62]  D. Ward,et al.  Cell cycle dependent chromosomal movement in pre-mitotic human T-lymphocyte nuclei , 1992, Chromosoma.

[63]  S. Mai,et al.  Genomic instability in MycER-activated Rat1A-MycER cells , 1996, Chromosome Research.

[64]  A. Bernheim,et al.  Initiation of the breakage-fusion-bridge mechanism through common fragile site activation in human breast cancer cells: the model of PIP gene duplication from a break at FRA7I. , 2002, Human molecular genetics.

[65]  D. Felsher,et al.  Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. , 2003, Blood.

[66]  Tobias A Knoch,et al.  Cell cycle-dependent 3D distribution of telomeres and telomere repeat-binding factor 2 (TRF2) in HaCaT and HaCaT-myc cells. , 2004, European journal of cell biology.

[67]  A. Hall,et al.  Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX , 2003, Oncogene.

[68]  D. Felsher,et al.  Reversible tumorigenesis by MYC in hematopoietic lineages. , 1999, Molecular cell.

[69]  M. Potter,et al.  Plasmacytomagenesis in mice: model of neoplastic development dependent upon chromosomal translocations. , 1992, Carcinogenesis.

[70]  S. Mandlekar,et al.  Pharmacodynamics of tamoxifen and its 4-hydroxy and N-desmethyl metabolites: activation of caspases and induction of apoptosis in rat mammary tumors and in human breast cancer cell lines. , 2000, Cancer research.

[71]  T. Ried,et al.  Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations , 2002, Oncogene.